A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer [Ann Oncol (2015), 26, 1923-1929]

B. H. O'Neil, A. J. Scott, Wen Wee Ma, S. J. Cohen, L. Leichman, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. RadfordL. Fehrenbacher, R. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes, W. A. Messersmith

Research output: Contribution to journalComment/debate

5 Scopus citations
Original languageEnglish (US)
Number of pages1
JournalAnnals of Oncology
Volume26
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

O'Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Leichman, L., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J., Coveler, L., Olowokure, O. O., Baranda, J. C., Cusnir, M., Phillip, P., Boles, J., Nazemzadeh, R., Rarick, M., Cohen, D. J., ... Messersmith, W. A. (2015). A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer [Ann Oncol (2015), 26, 1923-1929]. Annals of Oncology, 26(12). https://doi.org/10.1093/annonc/mdv477